01PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
EXPLORE THIS GOAL · MW
Metabolic + Weight
Appetite, glucose signaling and body composition. Use this dashboard to move between records, protocols, comparisons, research and tools.
01
Relevant peptides
02PEPTIDE
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Semaglutide
An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
CagriSema
An investigational fixed combination of cagrilintide and semaglutide studied in metabolic and weight-management trials.
Weight ManagementAppetiteGlucose / Insulin
05PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
06PEPTIDE
Cagrilintide
An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.
Weight ManagementAppetiteFat Loss
07PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
08PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
09PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
10PEPTIDE
AOD-9604
A modified growth-hormone fragment studied in metabolic and obesity research, with limited supportive clinical efficacy data.
Fat LossWeight ManagementBody Composition
11PEPTIDE
Tesamorelin
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.
Body CompositionFat LossNeuroendocrine
12PEPTIDE
5-Amino-1MQ
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
Fat LossBody CompositionMetabolic
13PEPTIDE
Ipamorelin
A selective ghrelin-receptor agonist studied as a growth hormone secretagogue, with limited modern human clinical evidence.
NeuroendocrineBody CompositionRecovery
14PEPTIDE
CJC-1295
A long-acting growth hormone-releasing hormone analogue studied in healthy adults for GH and IGF-1 pharmacodynamics.
NeuroendocrineBody CompositionRecovery
15PEPTIDE
Sermorelin
A GHRH(1-29) analogue formerly approved for pediatric diagnostic and treatment contexts and later discontinued commercially.
NeuroendocrineBody CompositionRecovery
02
Related protocols
03
Popular comparisons
04
Related research
SPONSOR UPDATETRIUMPH-1 Phase 3 topline resultsRetatrutide · Eli Lilly and Company · 2026SPONSOR UPDATETRIUMPH-2 and TRIUMPH-3 Phase 3 topline results and planned regulatory submissionRetatrutide · Eli Lilly and Company · 2026REGULATORYWhat to know about retatrutideRetatrutide · Eli Lilly and Company · 2026CLINICAL TRIALCoadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityCagriSema · New England Journal of Medicine · 2025CLINICAL TRIALTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver diseaseRetatrutide · Nature Medicine · 2024CLINICAL TRIALGlucagon and GLP-1 receptor dual agonist survodutide for obesitySurvodutide · The Lancet Diabetes & Endocrinology · 2024
05
Tools
06
Related goals
BUILD FROM THIS RESEARCH CONTEXT
Build a stack for Metabolic + Weight
The goal stays visible in the stack builder. Related records are suggestions by tag overlap; you choose what to add.